Peer-Reviewed Publications

    Assessment of single-photon ionization mass spectrometry for online monitoring of in vitro aerosol exposure experiments

    Frege, C.; Asgari, M.; Steiner, S.; Ferreira, S.; Majeed, S.; Lucci, F.; Frentzel, S.; Hoeng, J.; Kuczaj, A. K.

    Published
    Jan 7, 2020
    DOI
    10.1021/acs.chemrestox.9b00381
    PMID
    31909610
    Link to publication
    Topic
    Summary

    Chemical and physical characterization of transported evolving aerosols in an in vitro system is complex. The challenges include appropriate sampling sensitivity, measurement capabilities, and performing online measurements of constituents in the flowing aerosol during exposure. We assessed the performance of single-photon ionization mass spectrometry in measuring aerosol properties within an in vitro aerosol exposure system. The sampling efficiency of the instrument was studied under three protocols to capture the evolving aerosol process inside the exposure system, and it was evaluated using computational fluid dynamics modeling. The changes in the aerosol as dilution is applied show not only a reduction in concentration of the traced substances but also selective sampling due to evolution of the aerosol and (gas/liquid) phase partitioning of the substances forming the aerosol or a change in the aerosol properties. These effects have potentially a direct impact on the delivered dose, as aerosol deposition is dependent on particle size. Dilution affects the chemical concentration of the substances as well as the interconnected physical properties of the aerosol; therefore, the experimental design of in vitro studies should not only report the dilution flow rates but also details of the applied dilution protocol. This adds a layer of complexity to the design and comparison of studies. We also discuss the potential and limitations of single-photon ionization mass spectrometry as a tool in in vitro monitoring of aerosols.

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.